The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center

The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center

BackgroundEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could provide survival benefits for locally advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC). However, the role of radical surgery for EGFR-TKI treated stage IIIB EGFRm NSCLC remains controversial. This...

Full description

Bibliographic Details
Main Authors: Yicheng Xiong, Dongliang Bian, Zhida Huang, Huansha Yu, Jie Huang, Peng Zhang, Wenxin He, Hongcheng Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
adenocarcinoma
neoadjuvant targeted therapy
epidermal growth factor receptor
stage IIIB
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1034897/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1034897/full

Similar Items